It was a pleasure to speak with Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) around the rationale for the use of dupilumab in GINA-defined difficult to-treat type 2 asthma patients (Clinical Trial Identifier: NCT02414854).
The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions
- Could you tell us a little about dupilumab and the clinical evidence supporting its use in asthma patients? (0:52)
- How do the recent Global Initiative for Asthma (GINA) guidelines define difficult to treat and severe asthma? (3:38)
Disclosures: Klaus Rabe has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
